Acadian Asset Management LLC lessened its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) by 3.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,773 shares of the company’s stock after selling 3,499 shares during the quarter. Acadian Asset Management LLC owned 1.60% of Precision BioSciences worth $1,077,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Janus Henderson Group PLC purchased a new stake in Precision BioSciences during the first quarter worth about $7,739,000. 37.99% of the stock is currently owned by institutional investors.
Precision BioSciences Price Performance
Shares of NASDAQ DTIL opened at $10.33 on Tuesday. The business’s fifty day moving average price is $9.72 and its 200-day moving average price is $11.01. Precision BioSciences, Inc. has a one year low of $8.25 and a one year high of $19.43. The stock has a market capitalization of $71.55 million, a PE ratio of -1.38 and a beta of 1.70.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research report on Thursday, August 22nd.
Get Our Latest Stock Report on DTIL
Precision BioSciences Profile
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Further Reading
- Five stocks we like better than Precision BioSciences
- ETF Screener: Uses and Step-by-Step Guide
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Find Undervalued Stocks
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.